Shinji Nakaoka

Shinji Nakaoka

Auto-generated profile, based on publicly available information

Shinji Nakaoka

Faculty of Advanced Life Science, Hokkaido University, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
TYTomokazu Yamaguchi
Tomokazu Yamaguchi
TSTakashi Suzuki
Takashi Suzuki
TSTeruki Sato
Teruki Sato
ATAkinori Takahashi
Akinori Takahashi
HWHiroyuki Watanabe
Hiroyuki Watanabe
KKKeiji Kuba
Keiji Kuba
Destabilization of Atg7 mRNA by the CCR4-NOT complex prevents p53-dependent cell death in the heart.

6 July 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SIShoya Iwanami
Shoya Iwanami
KEKeisuke Ejima
Keisuke Ejima
KKKawang Su Kim
Kawang Su Kim
KNKoji Noshita
Koji Noshita
YFYasuhisa Fujita
Yasuhisa Fujita
TWTakaji Wakita
Takaji Wakita
Background: Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limited. The lack of evidence from clinical trials may stem in part from the imperfect design of the trials. We investigated how clinical trials for antivirals need to be designed, especially focusing on the sample size in randomized controlled trials. Methods and findings: A modeling study was conducted to help understand the reasons behind inconsistent clinical trial findings and to design better clinical trials. We first analyzed longitudinal viral load data for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) without antiviral treatment by use of a within-host virus dynamics model. The fitted viral load was categorized into 3 different groups by a clustering approach. Comparison of the estimated parameters showed that the 3 distinct groups were characterized by different virus decay rates (p-value < 0.001). The mean decay rates were 1.17 d−1 (95% CI: 1.06 to 1.27 d−1), 0.777 d−1 (0.716 to 0.838 d−1), and 0.450 d−1 (0.378 to 0.522 d−1) for the 3 groups, respectively. Such heterogeneity in virus dynamics could be a confounding variable if it is associated with treatment allocation in compassionate use programs (i.e., observational studies). Subsequently, we mimicked randomized controlled trials of antivirals by simulation. An antiviral effect causing a 95% to 99% reduction in viral replication was added to the model. To be realistic, we assumed that randomization and treatment are initiated with some time lag after symptom onset. Using the duration of virus shedding as an outcome, the sample size to detect a statistically significant mean difference between the treatment and placebo groups (1:1 allocation) was 13,603 and 11,670 (when the antiviral effect was 95% and 99%, respectively) per group if all patients are enrolled regardless of timing of randomization. The sample size was reduced to 584 and 458 (when the antiviral effect was 95% and 99%, respectively) if only patients who are treated within 1 day of symptom onset are enrolled. We confirmed the sample size was similarly reduced when using cumulative viral load in log scale as an outcome. We used a conventional virus dynamics model, which may not fully reflect the detailed mechanisms of viral dynamics of SARS-CoV-2. The model needs to be calibrated in terms of both parameter settings and model structure, which would yield more reliable sample size calculation. Conclusions: In this study, we found that estimated association in observational studies can be biased due to large heterogeneity in viral dynamics among infected individuals, and statistically significant effect in randomized controlled trials may be difficult to be detected due to small sample size. The sample size can be dramatically reduced by recruiting patients immediately after developing symptoms. We believe this is the first study investigated the study design of clinical trials for antiviral treatment using the viral dynamics model.

5 May 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
YNYusuke Nakano
Yusuke Nakano
NMNaoko Misawa
Naoko Misawa
GJGuillermo Juarez-Fernandez
Guillermo Juarez-Fernandez
MMMiyu Moriwaki
Miyu Moriwaki
SNShinji Nakaoka
Shinji Nakaoka
KSKei Sato
Kei Sato
APOBEC3 (A3) family proteins are DNA cytosine deaminases recognized for contributing to HIV-1 restriction and mutation. Prior studies have demonstrated that A3D, A3F, and A3G enzymes elicit a robust anti-HIV-1 effect in cell cultures and in humanized mouse models. Human A3H is polymorphic and can be categorized into three phenotypes: stable, intermediate, and unstable. However, the anti-viral effect of endogenous A3H in vivo has yet to be examined. Here we utilize a hematopoietic stem cell-transplanted humanized mouse model and demonstrate that stable A3H robustly affects HIV-1 fitness in vivo. In contrast, the selection pressure mediated by intermediate A3H is relaxed. Intriguingly, viral genomic RNA sequencing reveled that HIV-1 frequently adapts to better counteract stable A3H during replication in humanized mice. Molecular phylogenetic analyses and mathematical modeling suggest that stable A3H may be a critical factor in human-to-human viral transmission. Taken together, this study provides evidence that stable variants of A3H impose selective pressure on HIV-1. Human APOBEC3 family proteins are known as intrinsic defenses against HIV-1, whereas HIV-1 Vif counteracts APOBEC3-mediated anti-viral action. Using a hematopoietic stem cell-transplanted humanized mouse model, we demonstrated that endogenous APOBEC3D, APOBEC3F and APOBEC3G play pivotal roles in restricting HIV-1 replication in vivo. In addition to these three APOBEC3 family proteins, certain haplotypes of APOBEC3H have the ability to control HIV-1 replication in cell culture studies. However, the anti-viral effect of APOBEC3H polymorphism in vivo and in human population is yet to be addressed. Here we use a humanized mouse model to show that acquiring resistance to anti-viral APOBEC3H is necessary for HIV-1 replication. Together with phylogenetic analyses and mathematical modeling, we conclude that APOBEC3H is a critical determinant of HIV-1 replication within infected individuals and we propose that it may also be a factor in human-to-human HIV-1 transmission.

1 July 2018 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
KKKosaku Kitagawa
Kosaku Kitagawa
SNShinji Nakaoka
Shinji Nakaoka
YAYusuke Asai
Yusuke Asai
Koichi WatashiKoichi Watashi
Koichi Watashi
SIShingo Iwami
Shingo Iwami

1 July 2015 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
YKYusuke Kakizoe
Yusuke Kakizoe
SMSatoru Morita
Satoru Morita
SNShinji Nakaoka
Shinji Nakaoka
Yasuhiro TakeuchiYasuhiro Takeuchi
Yasuhiro Takeuchi
KSKei Sato
Kei Sato
SIShingo Iwami
Shingo Iwami

21 January 2014 in Theoretical Biology and Medical Modelling
Verified
Journal Article
Open access
PDF file
Hiroshi NishiuraHiroshi Nishiura
Hiroshi Nishiura
KEKeisuke Ejima
Keisuke Ejima
KMKenji Mizumoto
Kenji Mizumoto
SNShinji Nakaoka
Shinji Nakaoka
HIHisashi Inaba
Hisashi Inaba
MSMasaya M Saito
Masaya M Saito
There has been a variation in published opinions toward the effectiveness of school closure which is implemented reactively when substantial influenza transmissions are seen at schools. Parameterizing an age-structured epidemic model using published estimates of the pandemic H1N1-2009 and accounting for the cost effectiveness, we examined if the timing and length of school closure could be optimized.